MYK-461 is a myosin inhibitor that selectively decreases the ATPase activity of cardiac myosin heavy chain, thus it is potentially for the treatment of hypertrophic cardiomyopathy (HCM).
MYCMI-6 is a selective, high affinity inhibitor of MYC-MAX interaction. MYCMI-6 inhibits tumor cell growth in a MYC-dependent manner with IC50 concentrations as low as 0.5 μM, while sparing normal cells.
Mutant EGFR inhibitor is a potent and selective mutant EGFR inhibitor extracted from patent WO 2013014448 A1. It inhibits EGFRL858R, EGFRExon 19 deletionand EGFRT790M.
Mubritinib, also known as TAK-165, is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinical trials (may be discontinued since 2008). Mubritinib(TAK 165) is a potent EGFR, HER2 and p34cdc2 inhibitor with IC50 of 6 nM and 0.2 µM, respectively. Mubritinib(TAK 165) also inhibits p33cdk2 and p33cdk5. Mubritinib(TAK 165) displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. Mubritinib(TAK 165) exhibits potent antiproliferative effects in ErbB2-overexpressing cancer cell lines (IC50 = 5 nM in BT474 breast cancer cells) and significantly inhibits bladder, breast and prostate cancer xenograft growth in vivo.
MTDIA is a methylthioadenosine phosphorylase (MTAP) inhibitor. MTAP is responsible for 5'-methylthioadenosine (MTA) metabolism to permit S-adenosylmethionine salvage. Transition-state (TS) analogues of MTAP are in development as anticancer drug candidates and MTDIA is one of these TS analogues.
MTDIA is a human 5'-methylthioadenosine phosphorylase (MTAP) inhibitor, which is solely responsible for 5'-methylthioadenosine (MTA) metabolism to permit S-adenosylmethionine salvage. It is used as an anticancer candidate.
MSDC-0602 is an insulin sensitizer that has the potential to treat diabetes and other inflammatory diseases. It exhibits low affinity for binding and activation of PPARγ.
MS023 dihydrochloride is a potent, selective and cell-active human type I protein arginine methyltransferases (PRMTs) inhibitor, with IC50s of 30, 119, 83, 4 and 5 nM for PRMT1, PRMT3, PRMT4, PRMT6 and PRMT8, respectively.
MS023 is a Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases. MS023 displayed high potency for type I PRMTs including PRMT1, -3, -4, -6, and -8 but was completely inactive against type II and type III PRMTs, protein lysine methyltransferases and DNA methyltransferases.
MRTX849 is a potent and mutation-selective covalent inhibitor of KRAS G12C. It maximizes inhibition by irreversibly locking the KRAS molecule in its inactive state, thereby preventing tumor cell growth which results in tumor cell death.
MPEG2000-DSPE Sodium Salt can be used for the preparation of stabilized nucleic acid-lipid particllipid particles (SNALPs), which represent some of the earliest and best functional siRNA-ABC nanoparticles described.
An impurity of Moxifloxacin. Moxifloxacin is an antibiotic used to treat bacterial infenctions such as community acquired pneumonia, complicated skin infections and complicated intra-abdominal infections.
An impurity of Moxifloxacin. Moxifloxacin is an antibiotic used to treat bacterial infenctions such as community acquired pneumonia, complicated skin infections and complicated intra-abdominal infections.
Motesanib Diphosphate is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 2 nM/3 nM/6 nM, respectively; similar activity against Kit, ~10-fold more selective for VEGFR than PDGFR and Ret.
Motesanib is a multikinase inhibitor that selectively targets VEGF receptors, platelet-derived growth factor receptors (PDGFRs), and Kit receptors. It also potently inhibits angiogenesis and induces regression in tumor xenografts.
Mosapride Citrate Dihydrate is a citrate hydrate form of Mosapride, which is a 5-HT4 receptor agonist and 5-HT3 receptor antagonist. It is used as a gastroprokinetic agent.
Morin is a natural compound isolated from Maclura pomifera (Osage orange). Morin induces caspase-dependent apoptosis through extrinsic pathway by upregulating Fas receptor as well as through the intrinsic pathway by modulating Bcl-2 and IAP family members.
Morin induces caspase-dependent apoptosis through extrinsic pathway by upregulating Fas receptor as well as through the intrinsic pathway by modulating Bcl-2 and IAP family members.
An impurity of Montelukast Sodium, which is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies.
An impurity of Montelukast Sodium, which is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies.
An impurity of Montelukast Sodium, which is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies.
An impurity of Montelukast Sodium, which is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies.
